LHLHHealthcare · Diagnostics & Research

LH Stock Forecast: Labcorp Holdings, Inc. Price Predictions for 2026-2027

Last close, 10 Nov 2026
$371
−0.25% on the day

The 17 Wall Street analysts covering Labcorp Holdings, Inc. hold a median 12-month price target of $396 — +6.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 9 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$29.8B
Ticker Nerd rank
88/ 100
Median analyst target
$396
Analysts covering
17
Revenue$3.7B+5.8% y/y
Operating income$456.7M
Net income$299.1M
Free cash flow$313.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.8%
1M
+18.8%
YTD
+48.9%
1Y
+43.5%
From 52W high
−0.3%
From 52W low
+49.2%
$249
$372
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Labcorp Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 9 Nov 2026
88/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Revisions
90
Momentum
82
Quality
76
Issuance
66
Growth
64
Value
63
Accruals
62
Size
7

Volatility (99): The share price has been relatively steady.

Accruals (62): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Jan 26Apr 26Jul 26Oct 26LHHigh $420Median $396Low $347

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
13 Buy4 Hold0 Sell
Low $347Median $396High $420

The green dot is the last close — the median target sits +6.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 12 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 Oct 2026BairdMaintainsOutperform$361 → $396
29 Oct 2026BarclaysMaintainsEqual-Weight$330 → $380
29 Oct 2026Truist SecuritiesMaintainsBuy$365 → $395
29 Oct 2026UBSMaintainsBuy$380 → $420
21 Sept 2026Truist SecuritiesMaintainsBuy$350 → $365
21 Sept 2026Truist SecuritiesMaintainsBuy—
11 Sept 2026BarclaysMaintainsEqual-Weight$320 → $330
11 Sept 2026BarclaysMaintainsEqual-Weight—
11 Sept 2026UBSMaintainsBuy$361 → $380
11 Sept 2026UBSMaintainsBuy—
4 Aug 2026Piper SandlerMaintainsNeutral$300 → $309
4 Aug 2026Piper SandlerMaintainsNeutral—
3 Aug 2026JP MorganMaintainsOverweight$330 → $360
3 Aug 2026JP MorganMaintainsOverweight—
31 July 2026BarclaysMaintainsEqual-Weight$290 → $320
31 July 2026BarclaysMaintainsEqual-Weight—
31 July 2026Morgan StanleyMaintainsOverweight$308 → $338
31 July 2026Morgan StanleyMaintainsOverweight—
31 July 2026Truist SecuritiesMaintainsBuy—
31 July 2026Truist SecuritiesMaintainsBuy$320 → $350

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 10 Nov 2026, Labcorp Holdings, Inc. returned +43.5% against +11.6% for the S&P 500, dividends included.

LH vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26LHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+0.6%
Analysts raising
9
Analysts cutting
3
Fundamentals

Labcorp Holdings, Inc. (LH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.2×

Cheaper than 24% of US stocks

Price / sales
2.1×

Cheaper than 50% of US stocks

Price / book
3.4×

Cheaper than 27% of US stocks

EV / EBITDA
15.5×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
6.9%

Higher than 46% of US stocks

Earnings growth (YoY)
0.7%

Higher than 38% of US stocks

Gross margin
29.8%

Higher than 34% of US stocks

Operating margin
10.9%

Higher than 65% of US stocks

Net margin
6.9%

Higher than 64% of US stocks

Returns & dividend
Return on equity
11.4%

Higher than 66% of US stocks

Return on assets
5.5%

Higher than 78% of US stocks

Dividend yield
0.8%

Higher than 68% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Labcorp Holdings, Inc. (LH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Labcorp Holdings, Inc. has a market value of $29.8B and an enterprise value of $36.4B.

  • Revenue in the twelve months to 30 June 2026: $14.3B. The latest quarter grew 6.9% year on year.

  • Net income over the same four quarters: $1.0B, a 7.0% net margin.

  • Diluted earnings per share, trailing twelve months: $12.09.

  • Free cash flow in the twelve months to 30 June 2026: $1.2B, after $483.2M of capital spending.

  • Labcorp Holdings, Inc. spent $701.8M on share buybacks and $239.1M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 80.9M.

  • Trailing P/E: 30.2×; forward P/E: 18.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.78%, paying out 24% of earnings.

  • Labcorp Holdings, Inc. employs 71,000 people — $202K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Nov 2026

Data provided by Twelve Data

Peers

LH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
LHLabcorp Holdings, Inc.$29.8B88
DGXQuest Diagnostics, Inc.$28.9B94
ILMNIllumina, Inc.$33.3B95
MTDMettler-Toledo International, Inc.$36.0B96
IQVIQVIA Holdings, Inc.$45.9B85
GHGuardant Health, Inc.$20.5B46
NTRANatera, Inc.$46.5B72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Labcorp Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LH news & analysis

Is Now the Right Time to Hold Labcorp Stock in Your Portfolio?

Zacks Investment Research · 10 Nov 2026neutral

Zacks Investment Research highlights Labcorp’s specialty testing growth, AI-driven efficiencies, and expanding margins as supports for its outlook, while noting currency pressures and competition as risks.

Why it matters — LH watchers may weigh the operational growth drivers against the currency and competitive pressures described.

Labcorp Holdings (LH) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Investment Research · 5 Nov 2026positive

A Zacks Investment Research headline describes Labcorp Holdings as a top-ranked momentum stock and asks whether investors should buy. The excerpt says Zacks Style Scores are a feature of its Premium research service for identifying stocks across value, growth, and momentum approaches.

Why it matters — LH watchers may note the article's momentum-focused framing and its reference to Zacks' Style Scores.

Labcorp to Speak at the UBS Global Healthcare Conference

PRNewsWire · 4 Nov 2026neutral

Labcorp announced that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10, 2026, at 8:45 a.m.

Why it matters — LH watchers may note the scheduled conference appearance by the company’s chief financial officer.

Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research · 30 Oct 2026positive

Zacks Investment Research’s headline describes Labcorp Holdings (LH) as a top-ranked value stock. The excerpt says Zacks Style Scores are a feature of its Zacks Premium research service intended to help investors find strong stocks across value, growth, and momentum styles.

Why it matters — LH watchers may note the Zacks value-stock characterization and the research service feature behind it.

Labcorp Holdings: The Optimism May Be Going Overboard (Rating Downgrade)

Seeking Alpha · 29 Oct 2026negative

Labcorp raised guidance, prompting a sharp stock rally. The Seeking Alpha author sees a compelling long-term growth story but says the valuation is stretched, with the price-earnings ratio nearing 20, and downgraded the rating.

Why it matters — LH watchers may weigh the improved guidance against concerns that the current valuation exceeds the author’s preferred range for the company’s fundamentals.

FAQ

Frequently asked questions about LH stock

What is the LH stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Labcorp Holdings, Inc. have a median 12-month price target of $396, with estimates ranging from $347 to $420. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LH stock a buy right now?

Of the 17 analysts covering Labcorp Holdings, Inc., 13 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Labcorp Holdings, Inc. 88 out of 100 across roughly 4,600 US stocks as at 9 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LH?

As at 9 Nov 2026, Labcorp Holdings, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will LH stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +6.6% from the last close, and Ticker Nerd's factor model ranks Labcorp Holdings, Inc. 88 out of 100 as at 9 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LH stock forecast for 2030?

No analyst covering Labcorp Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $347 to $420 over the next 12 months.

How has LH stock performed over the past year?

Labcorp Holdings, Inc. returned +43.5% over the 12 months to 10 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Labcorp Holdings, Inc. do?

Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development.

What is the latest news on LH?

The most recent item we track (Zacks Investment Research, 10 Nov 2026): "Is Now the Right Time to Hold Labcorp Stock in Your Portfolio?". Zacks Investment Research highlights Labcorp’s specialty testing growth, AI-driven efficiencies, and expanding margins as supports for its outlook, while noting currency pressures and competition as risks.

Company

About Labcorp Holdings, Inc.

Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development. Labcorp Holdings Inc. serves doctors, hospitals, pharmaceutical companies, researchers, and patients through a broad portfolio that includes routine and specialty diagnostic testing, central laboratory services, and early development research support. Its Diagnostics Laboratories segment covers testing in areas such as oncology, women’s health, autoimmune disease, and neurology, while its Biopharma Laboratory Services segment supports pharmaceutical and biotech clients with laboratory capabilities for clinical trials and development programs. The company plays a key role in healthcare by helping customers generate data used in diagnosis, treatment decisions, and biomedical research.

CEO Mr. Adam H. Schechter · 71,000 employees · United States · https://www.labcorp.com